These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 27116231)
21. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years. Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754 [TBL] [Abstract][Full Text] [Related]
22. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051 [TBL] [Abstract][Full Text] [Related]
24. Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant. Pessoa B; Ferreira A; Leite J; Figueira J; Meireles A; Beirão JM Ophthalmic Res; 2021; 64(4):639-647. PubMed ID: 33601389 [TBL] [Abstract][Full Text] [Related]
25. Real-Life ILUVIEN (Fluocinolone Acetonide) Case Study: Rapid Drying of the Macula and Improved Vision within 2 Years after Therapy Initiation. Quhill H; Quhill F Case Rep Ophthalmol; 2016; 7(3):301-307. PubMed ID: 28203186 [TBL] [Abstract][Full Text] [Related]
26. Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE. Elbarky AM Clin Ophthalmol; 2020; 14():823-830. PubMed ID: 32214793 [TBL] [Abstract][Full Text] [Related]
29. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Currie CJ; Holden SE; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150 [TBL] [Abstract][Full Text] [Related]
30. Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant. Bertelmann T; Schulze S Ophthalmol Ther; 2015 Jun; 4(1):51-8. PubMed ID: 25672501 [TBL] [Abstract][Full Text] [Related]
31. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN Carneiro A; Meireles A; Castro Sousa JP; Teixeira C Ther Adv Ophthalmol; 2020; 12():2515841420917768. PubMed ID: 32548568 [TBL] [Abstract][Full Text] [Related]
32. The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema. Augustin AJ; Bopp S; Fechner M; Holz FG; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer MS; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H Eur J Ophthalmol; 2021 May; ():11206721211014728. PubMed ID: 33947233 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376 [TBL] [Abstract][Full Text] [Related]
34. Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema. El Rayes EN; Leila M Int J Retina Vitreous; 2023 Mar; 9(1):20. PubMed ID: 36991493 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of intravitreal Fluocinolone Acetonide microimplant (ILUVIEN Pacella F; Pacella E; Trovato Battagliola E; Malvasi M; Scalinci SZ; Turchetti P; Salducci M; Lucchino L; Arrico L Eur J Ophthalmol; 2021 May; ():11206721211020203. PubMed ID: 34030511 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy: The ILUvien in Postoperative CYstoid Macular eDema study. Motloch K; Soler V; Delyfer MN; Vasseur V; Wolff B; Issa M; Dot C; Massé H; Weber M; Comet A; Hitzl W; Matonti F; Creuzot-Garcher C; Tadayoni R; Kodjikian L; Couturier A Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39004282 [TBL] [Abstract][Full Text] [Related]
37. Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes. Coelho J; Malheiro L; Melo Beirão J; Meireles A; Pessoa B Clin Ophthalmol; 2019; 13():1751-1759. PubMed ID: 31571814 [TBL] [Abstract][Full Text] [Related]
38. Real-world experience with fluocinolone acetonide intravitreal implant in patients with diabetic macular edema. Capone L; Airaghi P; Aragona P; Castellino N; Cicinelli MV; Ciucci F; Coppola M; Gaetano C; Lattanzio R; Lorusso M; Maceroni M; Malvasi ME; Marco L; Marraffa M; Martini G; Mastropasqua R; Minnella AM; Nikolopulou E; Ortisi E; Pacella E; Papa V; Pennesi C; Reibaldi M; Rizzo S; Toto L; Trombetta L; Bandello F Eur J Ophthalmol; 2024 Feb; ():11206721241235266. PubMed ID: 38396370 [TBL] [Abstract][Full Text] [Related]